Glenmark Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Glenmark Pharmaceuticals Ltd. from all sources in a single place.

Glenmark Pharmaceuticals Ltd.

02 Jun 2025, 06:37PM

1497.50

2.77%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Full Dose - Esclation Data Show Continued High Response Rates and Favourable Safety Profile of ISB 2001, a First-in-Class BCMA x CD38 x CD3 Trispecific Antibody, for the Treatment of Relapsed/ Refractory Multiple Myeloma

pdf

Glenmark Pharmaceuticals Ltd.

27 May 2025

1497.50

2.77%

Earnings Call

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Further to our letter dated 19th May, 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings call held on Monday, May 26, 2025 for the fourth quarter ended March 31, 2025 has been uploaded on the Company''s website.

pdf

Glenmark Pharmaceuticals Ltd.

26 May 2025

1497.50

2.77%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Attaching herewith the Annual Secretarial Compliance Report for the Financial Year 2024-25.

pdf

Glenmark Pharmaceuticals Ltd.

26 May 2025

1497.50

2.77%

Earnings Call

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 FY 2024-25 earnings call held on 26th May, 2025 on the website of the Company.

pdf

Glenmark Pharmaceuticals Ltd.

26 May 2025

1497.50

2.77%

Glenmark Pharmaceuticals Results Earnings Call for Q4FY25 & Full Year

Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.

audio

Glenmark Pharmaceuticals Ltd.

26 May 2025

1497.50

2.77%

Glenmark Pharma Share Price Slumps After Q4 Results Miss Estimates

NDTV Profit

Glenmark Pharma reported a 6.3% increase in consolidated revenue, reaching Rs 3,256 crore compared to Rs 3,063 crore in the same quarter last year.

Glenmark Pharmaceuticals Ltd. is trading above its 150 day SMA of 1484.0

Glenmark Pharmaceuticals Ltd.

26 May 2025

1497.50

2.77%

EU and lower R&D spending drive 4Q earnings

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted a marginally lower-than-expected operating performance in 4QFY25 (2%/5% miss on revenue/EBITDA). Elevated interest outgo and lower other income led to a 16% miss on earnings.

Glenmark Pharmaceuticals Ltd. is trading above its 150 day SMA of 1484.0

Glenmark Pharmaceuticals Ltd.

23 May 2025

1497.50

2.77%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Intimation Under Regulation 30 Of Securities And Exchange Board Of …

BSE India

We wish to inform you that a wholly owned subsidiary company of GPL in the name of "Glenmark Consumer Care Limited" has been incorporated on May 23, 2025.

pdf